Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, the company's dividend and buyback decision, his thoughts on the ...

Paul Hudson, CEO of the pharmaceutical firm Sanofi, has an argument for letting AI make top-level decisions in medicine: It has no attachments. Speaking at a panel in Davos on Tuesday, Hudson said ...

Seqens, a developer and producer of active pharmaceutical ingredients, pharmaceutical intermediates, and specialty ingredients, has named Pascal Villemagne as Chief Executive Officer, effective April ...

Robert is currently chief digital officer at the cruise line firm Viking Cruises and will join Sanofi on 15th June. His brief is to drive Sanofi’s digital, data and technology strategy ...

On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...

Sanofi CEO Paul Hudson stated: “We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already ...

Sanofi CEO Paul Hudson said during the company’s Thursday investor call. More than 6 million babies around the world have now received Sanofi and AZ's preventative antibody, he added.

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...